Outlook Therapeutics, Inc. (OTLK) AI Stock Analysis

Outlook Therapeutics, Inc. is a late clinical-stage biopharmaceutical company focused on developing and commercializing monoclonal antibodies for ophthalmic conditions. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab in Phase III clinical trials designed to treat wet age-related macular degeneration and other retinal diseases. The company works with strategic partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd., to enhance clinical development and commercialization capabilities. Founded in 2010 and based in Iselin, New Jersey, it was previously known as Oncobiologics, Inc.

Revenue has fluctuated widely, increasing from $170,124 in FY2024 to $1.4M in FY2025, reflecting top-line growth of 730.9%. Despite this increase, the operating margin was -4744.3% in FY2025 following an operating margin of -42147.6% in FY2024. Outlook Therapeutics recorded a net loss of -$62.4M in FY2025 compared to -$75.4M in FY2024, while research and development expenses were $27.8M. For the trailing twelve months ending June 30, 2026, revenue stood at -$1.2M, with quarterly revenue declining 99.4% year-over-year and diluted EPS coming in at -$0.70.

As of June 30, 2026, Outlook Therapeutics held $11.2M in cash and short-term investments alongside total debt of $18.4M, resulting in net debt of $7.2M. The company operates with negative shareholders' equity of -$10.4M out of $26.2M in total assets, and it maintains a current ratio of 0.81. Operating cash flow in FY2025 was -$51.8M, which aligned with free cash flow of -$51.8M after $3 in capital expenditures. Over the past five years, the company's share count expanded by 170.8%.

At a market capitalization of $118.9M and enterprise value of $168.3M, Outlook Therapeutics trades at a price-to-sales multiple of 502.7x, compared to the median of 4.1x for its US-listed Healthcare peers. Its enterprise value to revenue multiple is 482.9x, while its forward price-to-earnings ratio is 2.8x compared to the peer median of 17.3x. The stock has underperformed the broader market, dropping 63.6% over the past year while the S&P 500 gained 16.8%, and declining 98.8% over five years.

Wall Street analysts currently assign Outlook Therapeutics 3 Strong Buy ratings, 1 Hold rating, and 0 Buy, Sell, or Strong Sell ratings. The average 12-month price target is $5.03, representing a 929.7% premium over the last close of $0.49. For the fiscal year ending September 30, 2026, consensus estimates project revenue of $682,670 and an EPS of -$0.43. For the following fiscal year, 3 analysts project revenue of $44.1M with an EPS of -$0.12. Outlook Therapeutics achieved 0 EPS beats over the last 4 quarters.

This page is an AI-written research summary of Outlook Therapeutics, Inc. (OTLK). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: OTLK income statement, OTLK balance sheet, OTLK key metrics, OTLK analyst forecast, OTLK chart. See the OTLK stock overview for the latest quote and news.